A recently published study found that a lecithin-based delivery form of Boswellia serrata from Indena, called Casperome, may be effective in reducing the duration of acute diarrhea in subjects with gastrointestinal infections.
Photo © iStockphoto.com/Artem_Furman
A recent study published in Nutrients1 found that a lecithin-based delivery form of Boswellia serrata from Indena, called Casperome, may be effective in reducing the duration of acute diarrhea in subjects with gastrointestinal infections. In the randomized, double-blind, placebo-controlled trial, 49 adults with acute diarrhea were given either placebo or 250 mg per day of the Boswellia serrata extract for five days. Results showed that supplementation with the extract demonstrated an 80% probability of recovering sooner from infection, as well as a significantly lower number of stools. There were also significant differences between the two groups in measures of abdominal pain, nausea, and global assessment of efficacy. Boswellia serrata may be effective for treating acute diarrhea because of its anti-inflammatory, antispasmodic, and antimicrobial activity.
“Boswellia serrata extract can act as a Ca2+ channels modulator and Casperome optimizes its delivery to the target organ: intestinal smooth muscles. Moreover, no side effects have been observed: Casperome counteracts motility unbalance, without slowing down the transit rate, and this is a major advantage since other agents induce constipation,” explained Antonella Riva, Indena’s head of product innovation and development, in a press release.
Reference
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.